161 related articles for article (PubMed ID: 2428787)
1. Thyroid lymphomas stages IE and IIE: comparative results for radiotherapy only, combination chemotherapy only, and multimodality treatment.
Vigliotti A; Kong JS; Fuller LM; Velasquez WS
Int J Radiat Oncol Biol Phys; 1986 Oct; 12(10):1807-12. PubMed ID: 2428787
[TBL] [Abstract][Full Text] [Related]
2. Stages IE and IIE non-Hodgkin's lymphomas of the stomach. Comparison of treatment modalities.
Maor MH; Maddux B; Osborne BM; Fuller LM; Sullivan JA; Nelson RS; Martin RG; Libshitz HI; Velasquez WS; Bennett RW
Cancer; 1984 Dec; 54(11):2330-7. PubMed ID: 6208989
[TBL] [Abstract][Full Text] [Related]
3. Outcome analysis for stage IE and IIE thyroid lymphoma.
DiBiase SJ; Grigsby PW; Guo C; Lin HS; Wasserman TH
Am J Clin Oncol; 2004 Apr; 27(2):178-84. PubMed ID: 15057158
[TBL] [Abstract][Full Text] [Related]
4. Stomach conservation in stages IE and IIE gastric non-Hodgkin's lymphoma.
Maor MH; Velasquez WS; Fuller LM; Silvermintz KB
J Clin Oncol; 1990 Feb; 8(2):266-71. PubMed ID: 1688927
[TBL] [Abstract][Full Text] [Related]
5. Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas.
Velasquez W; Fuller LM; Oh KK; Hagemeister FB; Sullivan JA; Manning JT; Shullenberger CC
Cancer; 1984 Apr; 53(7):1478-83. PubMed ID: 6199100
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies.
Green LD; Mack L; Pasieka JL
J Surg Oncol; 2006 Dec; 94(8):725-36. PubMed ID: 17131397
[TBL] [Abstract][Full Text] [Related]
7. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
8. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
9. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs.
Salles G; Herbrecht R; Tilly H; Berger F; Brousse N; Gisselbrecht C; Coiffier B
Am J Med; 1991 Jan; 90(1):77-84. PubMed ID: 1702581
[TBL] [Abstract][Full Text] [Related]
10. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy.
McLaughlin P; Fuller L; Redman J; Hagemeister F; Durr E; Allen P; Holmes L; Velasquez W; Swan F; Cabanillas F
Ann Oncol; 1991 Feb; 2 Suppl 2():137-40. PubMed ID: 1710918
[TBL] [Abstract][Full Text] [Related]
11. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
12. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
[TBL] [Abstract][Full Text] [Related]
13. Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy.
Bajetta E; Valagussa P; Bonadonna G; Lattuada A; Buzzoni R; Rilke F; Banfi A
Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):3-12. PubMed ID: 2455701
[TBL] [Abstract][Full Text] [Related]
14. Gastric lymphomas: chemotherapy as a primary treatment.
Solidoro A; Payet C; Sanchez-Lihon J; Montalbetti JA
Semin Surg Oncol; 1990; 6(4):218-25. PubMed ID: 1697094
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.
Jones SE; Miller TP; Connors JM
J Clin Oncol; 1989 Sep; 7(9):1186-91. PubMed ID: 2671279
[TBL] [Abstract][Full Text] [Related]
16. Stage I and II MALT lymphoma: results of treatment with radiotherapy.
Tsang RW; Gospodarowicz MK; Pintilie M; Bezjak A; Wells W; Hodgson DC; Crump M
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1258-64. PubMed ID: 11483337
[TBL] [Abstract][Full Text] [Related]
17. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
Reyes F; Lepage E; Ganem G; Molina TJ; Brice P; Coiffier B; Morel P; Ferme C; Bosly A; Lederlin P; Laurent G; Tilly H;
N Engl J Med; 2005 Mar; 352(12):1197-205. PubMed ID: 15788496
[TBL] [Abstract][Full Text] [Related]
18. Thyroid lymphoma. The case for combined modality therapy.
Doria R; Jekel JF; Cooper DL
Cancer; 1994 Jan; 73(1):200-6. PubMed ID: 8275426
[TBL] [Abstract][Full Text] [Related]
19. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity.
Wang B; Lu JJ; Ma X; Guo Y; Lu H; Hong X; Li J
Leuk Lymphoma; 2007 Feb; 48(2):396-402. PubMed ID: 17325902
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in non-Hodgkin's lymphoma.
Tubiana M; Carde P; Burgers JM; Cosset JM; Van Glabbeke M; Somers R
Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):503-14. PubMed ID: 3516950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
